BHCM
MDGL icon

Boulder Hill Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Boulder Hill Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-900
Closed -$218K – 141
2023
Q1 		$218K Buy
+900
New +$245K 0.18% 107

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Boulder Hill Capital Management's MDGL Position: Q2 2023 in Review

Boulder Hill Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 900 shares — an estimated $218K sold.

Boulder Hill Capital Management first reported a position in MDGL in Q1 2023 and held it in 1 quarter. The position peaked at $218K in Q1 2023. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

  • Boulder Hill Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 900 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $218K.
  • Boulder Hill Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Boulder Hill Capital Management's Madrigal Pharmaceuticals position peaked at $218K in Q1 2023.
  • 208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Boulder Hill Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.